JPS014 TFA - ≥98% , CAS No.J1420500

CAS: J1420500 Cat. No.: J1420500 Formula: C48H60F3N7O9S Molecular Weight: 968.09
AVAILABLE TO ORDER
GRADE & PURITY ≥98%
Storage
Store at 2-8°C,Protected from light,Argon charged
Shipped In
Wet ice
★
Size
Germany (EU)
USA*
Price
Qty
1mg
J1420500-1mg
Made to order · 8–12 wks
€1,042.07
Enter a quantity for the sizes you want to add.

Overview

JPS014 TFA is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimeras ( PROTAC ). JPS014 TFA degrades class I histone deacetylase ( HDAC ). JPS014 TFA is potent HDAC1/2 degrader correlated with greater total differentially expressed genes and enhanced apoptosis in HCT116 cells.

Specifications

Specifications & Purity
≥98%
Storage
Store at 2-8°C,Protected from light,Argon charged
Shipped In
Wet ice
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
DEGRADER
Purity
≥98%
Names and Identifiers
Molecular Weight
968.09

Advanced Data

Certificates (CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Application Protocols

No tested application protocols are provided for this item. As general guidance for small-molecule screening compounds (not item-specific):

  • Stock preparation: Dissolve in anhydrous DMSO to a convenient concentration (commonly 10–50 mM), vortex/sonicate as needed, and filter (0.22 µm) if particulate remains.
  • Dilution: Add to assay buffer or media as the final step to minimize precipitation; keep final DMSO ≤0.1–1% v/v as tolerated by your system.
  • Controls: Include vehicle controls and, where relevant, counterion controls (e.g., sodium trifluoroacetate) to rule out TFA effects.
  • Storage of working stocks: Aliquot and store frozen to avoid repeated freeze–thaw; monitor for precipitation or discoloration on thawing.

For any validated, item-specific methods (WB, IHC, IF, FC, enzyme assays, etc.), refer to project documentation or request technical support.

Biological Roles
  • Item-specific biological function: Not specified for this item; no target, pathway, or mechanism information is provided in the Product Data.

  • General context for small-molecule screening compounds (not item-specific):

    • Such compounds may serve as chemical probes or starting points in phenotypic or target-based assays. The TFA salt form facilitates handling and dissolution but does not imply any particular biological role.
    • Counterion considerations: Trifluoroacetate can mildly acidify solutions and may affect sensitive biological systems at higher concentrations. Control experiments with matched counterion blanks are prudent.
  • Experimental recommendations (general):

    • Establish baseline cytotoxicity or interference profiles in your assay system prior to interpreting activity.
    • Include DMSO-only and buffer-only controls, and if relevant, test equivalent concentrations of trifluoroacetic acid or sodium trifluoroacetate to rule out counterion effects.
    • Record exact salt form and concentration for reproducibility and for SAR interpretation across salt variants.

No clinical or therapeutic claims are made; this product is provided strictly for research use only.

Buffer Applications

This product is not a buffering agent. However, as a TFA salt, it may modestly acidify aqueous solutions.

  • Item-specific buffer data: Not specified for this item; refer to CoA/Spec Sheet.

  • General practical guidance (not item-specific):

    • When preparing assay solutions, use sufficiently strong buffers (e.g., 20–50 mM HEPES, PBS, or phosphate buffer) to minimize pH drift introduced by trifluoroacetate.
    • If pH neutrality is critical, consider neutralizing to the free base prior to dilution, or exchange the counterion (e.g., to chloride) via ion exchange or basify/acidify cycles.
    • Verify final solution pH after compound addition, especially at higher micromolar–millimolar concentrations.
  • Compatibility notes (general):

    • Avoid buffers containing high concentrations of amines (e.g., Tris) if they may engage in acid–base exchange with the salt form, potentially altering the compound’s state of ionization.
    • For LC–MS-coupled bioassays, formic or acetic acid is often preferred over TFA in mobile phases to reduce ion suppression.

This section provides general best practices only; no item-specific buffering parameters are available.

Green Alternatives

Because the structure-specific use pattern is unknown, solvent selection drives most environmental impact for small-molecule handling. The following comparison is general guidance for preparing solutions of TFA salts in a greener manner.

  • General solvent comparison (literature/general):

| Use case | Conventional choice | Greener alternative | Tradeoffs | |---|---|---|---| | Concentrated assay stocks | DMSO | Glycerol, PEG-400 (co-solvent), propylene carbonate | Higher viscosity; potential assay interference; sometimes lower solubility | | Workup/extraction | Dichloromethane, chloroform | Ethyl acetate, 2-MeTHF, CPME | Partitioning may differ; salts often remain in aqueous unless basified | | Recrystallization | Acetone/ACN | EtOAc/IPA/water systems | Solubility behavior is scaffold-dependent | | Mobile phase acid | TFA (0.1%) | Formic acid or acetic acid | Improved MS sensitivity; different chromatographic selectivity |

  • Practical green tips (general):
    • Minimize DMSO volumes by preparing the highest workable concentration, then dilute into buffered aqueous media immediately before use.
    • For desalting, use aqueous bicarbonate and eco-friendlier organics (EtOAc, 2-MeTHF) to extract the free base when compatible with the scaffold.
    • Favor aqueous or bio-based solvents when feasible, and employ micro-scale workflows to reduce waste.

Note: Implement changes only after verifying compound stability, solubility, and assay compatibility.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation specifications are provided for this item. It is supplied strictly for research use only and is not intended for human or veterinary use.

  • General considerations for salt forms in development (not item-specific):

    • Trifluoroacetate salts may improve crystallinity and handling during discovery. For development, non-TFA salts (e.g., HCl, sulfate, besylate) are often preferred due to regulatory familiarity and reduced risk of residual trifluoroacetate.
    • If this scaffold progresses, salt screening typically evaluates solubility, hygroscopicity, stability, and processability. Counterion exchange from TFA to development-friendly salts is routine.
    • Residual TFA can be monitored by 19F NMR or ion chromatography during process development.
  • Formulation notes (general):

    • For early in vitro work, stock solutions are commonly prepared in anhydrous DMSO and diluted into buffered media immediately prior to use. Verify adsorption losses to plastics and compatibility with excipients.

Refer to internal development SOPs and regulatory guidance for any use beyond discovery-stage research.

Physical Properties

Item-specific physicochemical data are not provided in the Product Data.

  • Item-specific values:

    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Melting point (MP): Not specified for this item; refer to CoA/Spec Sheet.
    • Boiling point (BP): Not applicable for most salts; if provided, defer to CoA/Spec Sheet.
    • Density: Not specified for this item; refer to CoA/Spec Sheet.
    • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
    • LogP / pKa / refractive index: Not specified for this item; refer to CoA/Spec Sheet.
  • General guidance for TFA salts (literature/general, not item-specific):

    • TFA salts of amines are often solids that can be hygroscopic. They commonly dissolve in polar solvents (e.g., water, methanol, ethanol, acetonitrile) and in high-percentage aqueous-organic systems; solubility in nonpolar solvents (hexanes, toluene) is typically poor.
    • The TFA counterion can modestly acidify aqueous solutions (pH often mildly acidic depending on concentration and the cation’s basicity). Adjust pH cautiously if the free base is required.
  • Practical note:

    • For assay stocks, many screening compounds are prepared at 10–50 mM in anhydrous DMSO as a general practice (general guidance). Validate actual solubility for this item empirically or by consulting the CoA.
Quality & Grades
  • Item-specific quality data:

    • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Research Use Note: For research use only.
  • Interpreting salt form (general guidance):

    • “TFA” indicates the trifluoroacetate salt. The salt form can enhance crystallinity and handling, and may improve aqueous solubility versus the free base. It can, however, introduce counterion-associated signals in analytical methods (e.g., LC–MS adducts, 19F NMR) and contribute acetate-related background in bioassays if not controlled.
  • Typical expectations for screening-library items (general):

    • Identity confirmation by NMR, MS, and/or HPLC purity assessment; exact acceptance criteria are lot-specific. UV cutoff, water/peroxide/metal limits, and stabilizers are often not defined for discovery compounds; consult the CoA if such controls are critical to your workflow.
  • Practical QA considerations:

    • If counterion mass complicates dose normalizations, convert to the free base via ion exchange or neutralization and re-salt as needed (document procedures and yields).
    • Ensure trace TFA does not interfere with pH-sensitive assays; consider desalting or buffering appropriately.
    • For LC–MS quantitation, monitor both the molecular ion and potential TFA adducts; verify response linearity in your matrix.

For definitive grade, purity, and analytical specifications, refer to the lot-specific CoA/Spec Sheet.

Reaction & Applications
  • Intended use (from Product Data): For research use only. No manufacturer application text is provided for this specific item.

  • General applications for small-molecule TFA salts (not item-specific):

    • Screening and SAR: Use as received to generate potency/phenotype data; document the salt form in assay records for reproducibility.
    • Reference/control: TFA salts can serve as stable, weighable forms for comparison across assay campaigns.
    • Conversion to free base: If neutral form is required for synthetic elaboration, liberate the free base by partitioning into organic solvent with aqueous base (e.g., NaHCO3/Na2CO3) or via ion-exchange resins, then re-salt to desired counterion as needed.
  • Analytical considerations (general):

    • LC–MS: Expect possible TFA adducts or signal suppression in positive ESI; use volatile alternative acids (e.g., formic acid) in mobile phases during quantitation when possible.
    • NMR: 19F resonance from TFA may be observed; confirm integration corresponds to stoichiometric counterion.
  • Practical workflow tips (general):

    • Prepare DMSO stocks under inert gas to minimize hydrolysis/oxidation if the scaffold is sensitive; aliquot to avoid freeze–thaw.
    • If pH-sensitive biology is planned, buffer dilutions sufficiently (≥20–50 mM) to mask counterion acidity, or neutralize/remake as a non-acidic salt (e.g., HCl) if compatible.
    • When comparing activity across salt forms, normalize dosing by free-base molecular weight if known.
Reaction Conditions

No item-specific reactivity or condition ranges are provided. The following general guidance applies to handling TFA salts when transitioning to synthetic operations (not item-specific):

  • Free base generation (general):

    • Aqueous route: Dissolve the TFA salt in water, wash with an immiscible organic solvent to remove neutrals, then basify (e.g., saturated NaHCO3 or 1–5% Na2CO3) and extract the liberated free base into an organic solvent (EtOAc, MTBE, DCM, 2-MeTHF). Dry and concentrate under reduced pressure.
    • Non-aqueous route: Suspend in anhydrous solvent (MeOH/EtOH/MeCN), add a non-nucleophilic base (iPr2NEt, Et3N) at 0–25°C, then proceed to in situ coupling if compatible.
  • Salt exchange (general):

    • Dissolve in minimal solvent, add the target acid (e.g., HCl in dioxane/ether or aqueous HCl) to precipitate the new salt; isolate by filtration and dry.
  • Analytical checkpoints:

    • Confirm removal/exchange of TFA by 19F NMR or ion chromatography; verify purity by HPLC/LC–MS.
  • Stability considerations:

    • Protect from light and moisture; maintain inert atmosphere when handling air-/moisture-sensitive scaffolds.

These are literature-style general procedures. Optimize conditions for the confirmed structure of JPS014 before scale-up.

Safety & Handling

Safety information specific to this item is not provided in the Product Data. Handle in accordance with good laboratory practice and consult the product SDS for authoritative guidance.

  • Item-specific hazard data:

    • GHS Classification: Not specified for this item; refer to SDS.
    • Signal Word / H-Statements / Pictograms: Not specified for this item; refer to SDS.
  • General precautions (good practice; not item-specific):

    • PPE: Use lab coat, safety glasses, and appropriate chemical-resistant gloves. Work in a chemical fume hood to avoid inhalation of dusts/aerosols.
    • Incompatibilities: Avoid strong bases or nucleophiles if maintaining the TFA salt form is critical; avoid moisture if the material is hygroscopic.
    • Special risks for TFA salts (general): Many amine–TFA salts can be mildly to strongly irritating; solutions may be acidic. Avoid contact with skin/eyes; rinse affected area with copious water. Seek medical attention if irritation persists.
  • Storage & handling conditions (item-specific from Product Data):

    • Store at 2–8°C, protected from light, argon charged.
    • Shipped on wet ice.
    • Maintain under inert gas to limit oxidative or hydrolytic degradation; allow to warm to room temperature before opening to minimize condensation.
  • First-aid overview (general):

    • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing.
    • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.

Always defer to the SDS for definitive hazard communication.

Solvent Selection

This product is a small-molecule TFA salt; solvent strategy depends on the underlying scaffold. Item-specific solubility is not provided.

  • Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet.

  • General solvent guidance for TFA salts (literature/general):

    • Highly recommended stock solvent: anhydrous DMSO (typical 10–50 mM screening stocks). Test for stability and solubility.
    • Often soluble: water, methanol, ethanol, acetonitrile; solubility increases with ionic/polar functional groups.
    • Often limited: nonpolar solvents (hexanes, cyclohexane, toluene) unless the cation is highly lipophilic.
    • Aqueous buffers: mild acidity from TFA may lower pH; adjust with dilute base only if converting to free base is acceptable.
  • Dielectric/polarity considerations (general):

    • Polar aprotics (DMSO, DMF, NMP, MeCN) stabilize ionic species and generally enhance dissolution of TFA salts.
  • Quick comparison (general):

    • DMSO: maximal solubilization for diverse scaffolds; biologically compatible at ≤1% v/v in many assays.
    • MeOH/EtOH: easy to remove, miscible with water; may denature proteins at higher %.
    • Water/buffer: preferred for biocompatibility; verify stability and pH.
  • Practical tips:

    • Sonication and mild warming (≤37°C) can help dissolve solids; avoid prolonged heating.
    • Filter (0.22 µm) before bioassays to remove particulates.
    • Record the salt form and concentration on vials to avoid molarity miscalculations.
Storage & Reconstitution
  • Item-specific storage/shipping (from Product Data):

    • Store at 2–8°C.
    • Protect from light.
    • Argon charged; maintain under inert atmosphere when possible.
    • Shipped on wet ice.
  • Stability notes (general):

    • TFA salts can be hygroscopic; minimize headspace and moisture ingress. Allow vials to equilibrate to room temperature before opening to prevent condensation. Re-cap promptly and purge with argon/nitrogen after use.
  • Reconstitution guidance (general, not item-specific):

    • For screening use: Prepare an anhydrous DMSO stock (e.g., 10–50 mM as typical practice) based on the known molecular weight of the salt or, preferably, the free-base equivalent if dosing by free-base molarity. If the MW is not available, request the CoA before preparing calibrated stocks.
    • For aqueous preparations: Use buffered solutions (e.g., 20–50 mM HEPES or phosphate) to mitigate acidity from TFA; confirm pH after dissolution.
    • Filtration: If insoluble matter persists, filter through a 0.22 µm PTFE or PVDF membrane.
  • Freeze–thaw management (general):

    • Aliquot stocks to single-use vials; avoid multiple freeze–thaw cycles.
    • Store DMSO stocks at ≤−20°C protected from light; inspect for precipitation or phase separation upon thaw.

Always refer to the lot-specific CoA/SDS for definitive stability, reconstitution concentration limits, and storage durations.

Structure & Identity

Brief overview: This listing is for a small-molecule screening compound denoted “JPS014 TFA,” indicating a trifluoroacetate (TFA) salt form. Item-specific structural identifiers are not provided in the Product Data.

  • Item-specific identifiers (from Product Data):

    • SKU: J1420500
    • Product Name: JPS014 TFA
    • CAS: Not specified for this item; refer to CoA/Spec Sheet.
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Interpreting the name (general chemistry knowledge):

    • “TFA” denotes the trifluoroacetate salt, typically formed when a basic center (commonly an amine) is protonated by trifluoroacetic acid (CF3CO2H) to give an R–NH3+ · CF3CO2− salt. The exact cationic scaffold for “JPS014” is not specified.
  • Structural features (general expectations for TFA salts):

    • Counterion: trifluoroacetate anion (CF3–COO−) is strongly electron-withdrawing and non-nucleophilic.
    • The organic cation’s ring systems, functional groups, and stereochemistry are unknown for this specific item and should be confirmed from the CoA/SDS/structure file supplied with the lot.
  • 2D structure description (item-specific):

    • Not specified for this item; refer to CoA/Spec Sheet. If needed, request the SDF/MOL file from Aladdin Scientific customer support for cheminformatics integration.
Synthetic Utility

Item-specific functional groups are not disclosed. Nevertheless, the TFA salt designation offers general synthetic implications:

  • General transformations enabled by TFA salts of amines (not item-specific):

    • Free base liberation: Treat an aqueous solution with NaHCO3/Na2CO3 or an organic solution with a non-nucleophilic base (e.g., iPr2NEt) to generate the free base for subsequent reactions (acylation, alkylation, coupling).
    • Salt metathesis: Exchange TFA for alternative counterions (HCl, mesylate, tosylate) using ion-exchange resins or acid–base cycles to tune solubility and crystallinity.
    • Purification aid: The TFA salt can improve crystallization and facilitate separation from neutral/byproduct impurities.
  • Analytical leverage (general):

    • 19F NMR signal from CF3 group enables counterion quantitation and can assist in tracking desalting efficiency.
  • Cautions:

    • Basic conditions can partially neutralize the salt, impacting reaction stoichiometry; standardize on free-base equivalents.
    • Certain nucleophilic reactions may be inhibited by residual acid; ensure adequate neutralization and drying before moisture/acid-sensitive steps.

Because the core scaffold of “JPS014” is unspecified, devise reaction plans only after confirming structure and functional groups from the CoA/structure file.

Target Specificity

Not applicable. This product is a small-molecule compound from a screening library; no antibody/biologic target, clone, or isotype information is relevant or provided. Item-specific target data are not specified for this item; refer to CoA/Spec Sheet if available.

Frequently Asked Questions

What is the purity of this product?
This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.
How should this product be stored?
Store at 2–8 °C, protected from light, under argon. It is supplied under an argon blanket; reseal under inert gas after each use.
How is this product shipped?
This product ships chilled on wet ice. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is J1420500, the molecular formula is C48H60F3N7O9S, and the molecular weight is 968.09 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.